Short answer
Immunome Inc. (IMNM) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). $20.0M cash plus 4,425,487 shares paid to BMS for full ownership of varegacestat and AL101 patent rights.
Immunome Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $20.0M cash plus 4,425,487 shares paid to BMS for full ownership of varegacestat and AL101 patent rights
- Elimination of all future milestone, royalty and other BMS payment obligations improves economics of the programs
- Share issuance creates dilution and potential selling pressure once BMS resale registration becomes effective
- Resale registration targeted by November 16, 2026, with effectiveness required within 60 calendar days after filing
Item 3.02 · Unregistered Sales of Equity Securities
- Immunome issued shares to Bristol Myers Squibb under a Stock Issuance Agreement, creating potential dilution for existing shareholders
- Private-placement exemption under Securities Act Section 4(a)(2), avoiding immediate public registration
- BMS shares remain restricted and cannot be resold in the United States without registration or another exemption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunome Inc. 8-K filings
Get the next IMNM 8-K as it lands
Follow IMNM for push alerts, or ask the research agent what this filing means.